Tumor lysis syndrome medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 7: Line 7:


==Medical Therapy==
==Medical Therapy==
*Intravenous fluids:<ref name="pmid15384972">{{cite journal| author=Cairo MS, Bishop M| title=Tumour lysis syndrome: new therapeutic strategies and classification. | journal=Br J Haematol | year= 2004 | volume= 127 | issue= 1 | pages= 3-11 | pmid=15384972 | doi=10.1111/j.1365-2141.2004.05094.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15384972}}</ref><ref name="JonesWill2015">{{cite journal|last1=Jones|first1=Gail L|last2=Will|first2=Andrew|last3=Jackson|first3=Graham H|last4=Webb|first4=Nicholas J A|last5=Rule|first5=Simon|title=Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology|journal=British Journal of Haematology|volume=169|issue=5|year=2015|pages=661–671|issn=00071048|doi=10.1111/bjh.13403}}</ref>
The treatment of tumor lysis syndrome is a multidisciplinary effort between nephrologist, hematologist, and intensivist.<ref name="pmid15384972">{{cite journal| author=Cairo MS, Bishop M| title=Tumour lysis syndrome: new therapeutic strategies and classification. | journal=Br J Haematol | year= 2004 | volume= 127 | issue= 1 | pages= 3-11 | pmid=15384972 | doi=10.1111/j.1365-2141.2004.05094.x | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15384972}}</ref><ref name="JonesWill2015">{{cite journal|last1=Jones|first1=Gail L|last2=Will|first2=Andrew|last3=Jackson|first3=Graham H|last4=Webb|first4=Nicholas J A|last5=Rule|first5=Simon|title=Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology|journal=British Journal of Haematology|volume=169|issue=5|year=2015|pages=661–671|issn=00071048|doi=10.1111/bjh.13403}}</ref>
*Intravenous fluids:
:*Aggressive hydration (3 l/m2/d)
:*Aggressive hydration (3 l/m2/d)
::*Maintain [[urine output]] 4ml/kg/h for infants and 100ml/m2/h for adults
::*Maintain [[urine output]] 4ml/kg/h for infants and 100ml/m2/h for adults

Revision as of 14:09, 30 September 2015

Tumor lysis syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tumor lysis syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tumor lysis syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tumor lysis syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tumor lysis syndrome medical therapy

CDC on Tumor lysis syndrome medical therapy

Tumor lysis syndrome medical therapy in the news

Blogs on Tumor lysis syndrome medical therapy

Directions to Hospitals Treating Tumor lysis syndrome

Risk calculators and risk factors for Tumor lysis syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]

Overview

Tumor lysis syndrome is a medical emergency and requires prompt treatment. [1]

Medical Therapy

The treatment of tumor lysis syndrome is a multidisciplinary effort between nephrologist, hematologist, and intensivist.[2][3]

  • Intravenous fluids:
  • Aggressive hydration (3 l/m2/d)
  • Maintain urine output 4ml/kg/h for infants and 100ml/m2/h for adults
  • Avoid adding potassium in hydration fluids
  • Fluid loss should be measured, such as vomiting and diarrhea
  • Elderly, infants, and patients with cardiac disease are at high risk of developing hypervolemia
  • Note: Alkalization of urine is not recommended to increase the excretion of uric acid (the use of sodium bicarbonate is controversial).[4]
  • Electrolytes disturbance:
  • Avoid intra venous phosphate
  • Aluminium hydroxide (15 ml q6h)
  • Asymptomatic: not treatment needed
  • Symptomatic: calcium gluconate (50–100 mg/kg IV)
  • Asymptomatic (≥6·0 mmol/l): avoid potassium administration, ECG, and sodium polystyrene sulphonate
  • Symptomatic (>7·0 mmol/l): add calcium gluconate (100–200 mg/kg) IV and/or regular insulin (0·1 unit/kg IV) + D25 (2 ml/kg) IV, and dialysis
  • Allopurinol (10 mg/kg/d divided q8 h), reduce the dose by 50% in renal failure
  • Rasburicase ( 0·05–0·20 mg/kg IV over 30 min)


  • Acute renal failure prior to chemotherapy:
  • Acute renal failure after chemotherapy:
  • The major cause of acute renal failure in this setting is hyperphosphatemia, and the main therapeutic means is hemodialysis. Forms of hemodialysis used include continuous arteriovenous hemodialysis (CAVHD), continuous venovenous hemofiltration (CVVH), or continuous venovenous hemodialysis (CVVHD).

References

  1. Jeha S (2001). "Tumor lysis syndrome". Semin Hematol. 38 (4 Suppl 10): 4–8. PMID 11694945.
  2. Cairo MS, Bishop M (2004). "Tumour lysis syndrome: new therapeutic strategies and classification". Br J Haematol. 127 (1): 3–11. doi:10.1111/j.1365-2141.2004.05094.x. PMID 15384972.
  3. Jones, Gail L; Will, Andrew; Jackson, Graham H; Webb, Nicholas J A; Rule, Simon (2015). "Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology". British Journal of Haematology. 169 (5): 661–671. doi:10.1111/bjh.13403. ISSN 0007-1048.
  4. Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst MM (1998). "Alkalinization and the tumor lysis syndrome". Med Pediatr Oncol. 31 (1): 27–8. PMID 9607427.

Template:WH Template:WS